CYC-202 Cyclacel.
CYC-202, the lead compound from the CYC-200 series of small-molecule cyclin-dependent kinase inhibitors, is under development by Cyclacel for the potential treatment of various cancers and inflammatory diseases, including glomerulonephritis. The compound is currently undergoing phase II clinical trials in non-small-cell lung cancer and breast tumor.
Guzi
Timothy
T
Schering-Plough Research Institute, Chemical Research, Infectious Diseases and Tumor Biology, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. timothy.guzi@spcorp.com
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D011687:Purines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000077546:Roscovitine
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011687:Purines; D000077546:Roscovitine